AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Previously presented) A method of preventing or treating rejection of a grafted cell, tissue, or organ in a mammal comprising administering to the mammal a composition comprising a purified complex consisting essentially of a heat shock protein non-covalently bound to a peptide, wherein the peptide is not an alloantigen of the grafted cells, tissue, or organ, and wherein the heat shock protein is not hsp60 or cpn10.

2. (Original) The method of claim 1, wherein the heat shock protein is not an alloantigen of the grafted cells, tissue, or organ.

3-5 (Canceled)

6. (Previously presented) The method of claim 1, wherein the grafted cell, tissue, or organ is skin, liver, kidney, heart, bone marrow, pancreas, lung, cornea, cartilage, or a cell derived therefrom.

7. (Original) The method of claim 6, wherein the grafted cell or tissue is skin or a cell derived from skin.

8. (Previously presented) The method of claim 1, wherein the heat shock protein is mammalian.

9. (Original) The method of claim 8, wherein the heat shock protein is human.

10. (Original) The method of claim 8, wherein the heat shock protein is gp96.

11. (Original) The method of claim 8, wherein the heat shock protein is hsp70.

12. (Original) The method of claim 8, wherein the heat shock protein is hsp90.

13. (Previously presented) The method of claim 1 or 2, wherein the mammal is human.

14. (Previously presented) The method of claim 1, comprising administering the composition before the cell, tissue, or organ is grafted.

15. (Previously presented) The method of claim 1, comprising administering the composition after the cell, tissue, or organ is grafted.

16. (Currently amended) The method of claim 1, wherein the amount of the ~~heat shock protein~~ complex present in the composition is in a range of 5 μg to 5,000 μg.

17. (Currently amended) The method of claim 1, wherein the amount of the ~~heat shock protein~~ complex present in the composition is 100 μg or more.

18. (Currently amended) The method of claim 1, wherein the amount of the ~~heat shock protein~~ complex present in the composition is 200 μg or more.

19. (Original) The method of claim 14, further comprising administering to the mammal a sample of cells or tissue obtained from the cell, tissue, or organ donor prior to administration of the heat shock protein.

20. (Canceled)

21. (Previously presented) The method of claim 1, wherein the peptide is not a bacterial peptide.

22-31 (Canceled)

32. (Previously presented) The method of claim 1, wherein said composition comprises a purified population of complexes, each complex in said population consisting essentially of a heat shock protein non-covalently bound to a peptide, and wherein each peptide is independently selected from a population of different peptides.

33. (New) A method of preventing or treating rejection of a grafted cell, tissue, or organ in a mammal comprising administering to the mammal a composition comprising a purified complex consisting essentially of a heat shock protein non-covalently bound to a peptide, wherein the peptide is not an alloantigen of the grafted cells, tissue, or organ, and wherein the heat shock protein is a member of the hsp90 family of heat shock proteins.

34. (New) A method of preventing or treating rejection of a grafted cell, tissue, or organ in a mammal comprising administering to the mammal a composition comprising a

purified complex consisting essentially of a heat shock protein non-covalently bound to a peptide, wherein the peptide is not an alloantigen of the grafted cells, tissue, or organ, and wherein the heat shock protein is a member of the hsp70 family of heat shock proteins.

35. (New) The method of claim 33 or 34, wherein the heat shock protein is not an alloantigen of the grafted cells, tissue, or organ.

36. (New) The method of claim 33 or 34, wherein the grafted cell, tissue, or organ is skin, liver, kidney, heart, bone marrow, pancreas, lung, cornea, cartilage, or a cell derived therefrom.

37. (New) The method of claim 33 or 34, wherein the grafted cell or tissue is skin or a cell derived from skin.

38. (New) The method of claim 33 or 34, wherein the heat shock protein is mammalian.

39. (New) The method of claim 33 or 34, wherein the heat shock protein is human.

40. (New) The method of claim 33, wherein the heat shock protein is gp96.

41. (New) The method of claim 33, wherein the heat shock protein is hsp90.

42. (New) The method of claim 34, wherein the heat shock protein is hsp70.

43. (New) The method of claim 33, 34, or 35, wherein the mammal is human.

44. (New) The method of claim 33 or 34, comprising administering the composition before the cell, tissue, or organ is grafted.

45. (New) The method of claim 33 or 34, comprising administering the composition after the cell, tissue, or organ is grafted.

46. (New) The method of claim 33 or 34, wherein the amount of the complex present in the composition is in a range of 5 μg to 5,000 μg.

47. (New) The method of claim 33 or 34, wherein the amount of the complex present in the composition is 100 μg or more.

48. (New) The method of claim 33 or 34, wherein the amount of the complex present in the composition is 200 μg or more.

49. (New) The method of claim 33 or 34, further comprising administering to the mammal a sample of cells or tissue obtained from the cell, tissue, or organ donor prior to administration of the heat shock protein.

50. (Previously presented) The method of claim 33 or 34, wherein the peptide is not a bacterial peptide.

51. (New) The method of claim 33 or 34, wherein said composition comprises a purified population of complexes, each complex in said population consisting essentially of a heat shock protein non-covalently bound to a peptide, and wherein each peptide is independently selected from a population of different peptides.

52. (New) The method of claim 33, wherein the heat shock protein is human gp96, and wherein the mammal is human.